Champions Oncology (CSBR) EPS (Basic) (2016 - 2026)
Champions Oncology has reported EPS (Basic) over the past 17 years, most recently at -$0.02 for Q1 2026.
- Quarterly results put EPS (Basic) at -$0.02 for Q1 2026, down 106.06% from a year ago — trailing twelve months through Jan 2026 was -$0.17 (down 136.17% YoY), and the annual figure for FY2025 was $0.34, up 162.96%.
- EPS (Basic) for Q1 2026 was -$0.02 at Champions Oncology, down from $0.02 in the prior quarter.
- Over the last five years, EPS (Basic) for CSBR hit a ceiling of $0.33 in Q1 2025 and a floor of -$0.19 in Q2 2023.
- Median EPS (Basic) over the past 5 years was -$0.02 (2022), compared with a mean of -$0.03.
- Biggest five-year swings in EPS (Basic): tumbled 12576.4% in 2023 and later soared 273.68% in 2025.
- Champions Oncology's EPS (Basic) stood at -$0.0 in 2022, then crashed by 12576.4% to -$0.15 in 2023, then surged by 133.33% to $0.05 in 2024, then plummeted by 60.0% to $0.02 in 2025, then tumbled by 200.0% to -$0.02 in 2026.
- The last three reported values for EPS (Basic) were -$0.02 (Q1 2026), $0.02 (Q4 2025), and -$0.03 (Q3 2025) per Business Quant data.